A Magnetic T7 Peptide&AS1411 Aptamer-Modified Microemulsion for Triple Glioma-Targeted Delivery of Shikonin and Docetaxel

Glioma-targeted drug delivery is a hugely challenging task because of the multibarrier in brain. In this study, we report magnetic T7 peptide&AS1411 aptamer-modified microemulsion for triple glioma-targeted shikonin and docetaxel (Fe3O4@T7/AS1411/DTX&SKN-M). Such system comprises two tumor-targeted ligands (T7 peptide AS1411 aptamer), ultra-small superparamagnetic iron oxide nanoparticle (Fe3O4), shikonin&docetaxel-coloaded (SKN&DTX-M). Fe3O4@T7/AS1411/DTX&SKN-M capable stably circulating blood, accumulating around brain under an external field, distributing inside glioma via affinity to nucleolin/transferrin receptor, retarding growth orthotopic glioma. encapsulated Fe3O4 nanoparticles core obtain superparamagnetism, which did not influence main surface properties. Introducing 6% (wt%) DSPE-PEG2000-T7 180 nM collaboratively enhanced murine (G422) cellular uptake thereby achieved strongest antiproliferation among all groups. Notably, distribution at sites Luc-G422 tumor-bearing nude mice treated with was overwhelming treatments. Most importantly, only significantly reduced luminescence signal areas but also prolonged overall survival period. The enhancement anti-glioma efficacy associated down-regulating population CD133- CD44-positive cells within tumors. summary, such using combinational magnetism T7/AS1411 modification strategies provides promising method synergistic precise therapy.